Neuraxis

Neuraxis Net Margin

The Net Profit Margin of Neuraxis (NRXS) as of Nov 22, 2026 is -218.55 %. In the previous year, Net Profit Margin was -306.84 % — a change of -28.78% (higher).

Net Margin

-218.55 %

YoY

-28.78%

Last updated:

Net Profit Margin of Neuraxis is 2025 -218.55 % . Net Profit Margin of Neuraxis was 2024 -306.84 % . It decreases by -28.78% higher compared to the previous year.

For Neuraxis, the net margin of -218.5% is down versus -111.3% a few years ago.

The Neuraxis Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
-193.04 USD
Jan 1, 2021
-111.27 USD
Jan 1, 2022
-178.05 USD
Jan 1, 2023
-594.57 USD
Jan 1, 2024
-306.84 USD
Jan 1, 2025
-218.55 USD
The Neuraxis Net Margin history
YEARNet MarginYoY
-218.55 %-28.78%
-306.84 %-48.39%
-594.57 %+233.94%
-178.05 %+60.01%
-111.27 %-42.36%
-193.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Net Profit Margin of Neuraxis is -218.55 % in 2025.

Net Profit Margin of Neuraxis changed from -306.84 % to -218.55 %, representing a -28.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Neuraxis

All Key Metrics — Neuraxis